NCT04807309

PRETELL: PREvention of TELomere-related Complications After Lung Transplant

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of Danzol in lung transplant recipients with short telomeres. Subjects with short telomeres recipient of lung transplant, will be randomized in the first month post-transplant to either placebo or Danazol (200mg bid) in a 2:1 ratio.

Conditions

• Short Telomere Length
• Lung Transplant

Interventions

Type	Name	Description
DRUG	Danazol Pill	Danazol 200 mg orally twice a day
DRUG	Placebo	Placebo twice a day

Timeline

• Start date: 2021-01-01
• Primary completion: 2021-11-20
• Completion: 2022-01-01
• First posted: 2021-03-19
• Last updated: 2023-02-15

Regulatory

• FDA-regulated drug study